NCT06884033

Brief Summary

Group cinematherapy program in reducing depressive and anxiety symptoms in women diagnosed with Depressive Disorders and Anxiety Disorders.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 10, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 19, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2025

Completed
Last Updated

August 12, 2025

Status Verified

March 1, 2025

Enrollment Period

6 months

First QC Date

March 10, 2025

Last Update Submit

August 11, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Assessment of change from baseline in anxiety symptoms.

    The presence and degree of anxiety will be assessed using the Hamilton Anxiety Rating Scale (HARS). The scale consists of 14 items designed to assess the severity of a patient's anxiety. Each of the 14 items contains a number of symptoms, and each group of symptoms is rated on a scale of zero to four, with four being the most severe. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity. Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity.

    8 months

  • Assessment of change from baseline in depression symptoms.

    The presence and degree of depression will be assessed using the Hamilton Depression Rating Scale (HDRS). The scale contains 17 items pertaining to symptoms of depression experienced over the past week. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.

    8 months

Secondary Outcomes (4)

  • Weight will be collected for all patients.

    8 months

  • Eight will be collected for all patients.

    8 months

  • Body mass index (BMI) will be collected for all patients.

    8 months

  • Heart rate variability (HRV) will be collected for all patients.

    8 months

Study Arms (1)

Cinematherapy intervention

EXPERIMENTAL

Cinematherapy intervention

Behavioral: Cinematherapy

Interventions

CinematherapyBEHAVIORAL

Cinematherapy, also known as cinema therapy and movie therapy, involves therapist-directed viewing of movies for specific therapeutic purposes.

Cinematherapy intervention

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • female, aged 18-75 years;
  • Diagnosis of Depressive Disorders (unipolar and bipolar) and Anxiety Disorders according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5), both new onset in subjects without a previous psychiatric history, and depressive and anxious recurrences;
  • Taking psychopharmacological therapy;
  • Fluent knowledge of the Italian language;
  • Release of a written informed consent, signed by the patient or legal representative and partner.

You may not qualify if:

  • Diagnosis of Schizophrenia or other psychotic spectrum disorders;
  • Diagnosis of neurological disorders associated with cognitive decline;
  • Current abuse of alcohol and psychotropic substances, with the exception of smoking;
  • Refusal to sign the informed consent to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marianna Mazza

Rome, ROMA, 00168, Italy

Location

Study Officials

  • Marianna Mazza

    Fondazione Policlinico Universitario A. Gemelli, IRCCS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 10, 2025

First Posted

March 19, 2025

Study Start

January 15, 2025

Primary Completion

July 15, 2025

Study Completion

July 15, 2025

Last Updated

August 12, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations